Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Nurix, Celgene partner to develop new therapies for oncology immunology and immuno-oncology
Nurix and Celgene have partnered to develop and commercialize novel small molecule therapeutics in the fields of oncology, inflammation, immunology and immuno-oncology.
FDA Warnings Target Drug Companies in New Zealand, India
Sept.
Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma
PRINCETON, N.
Obama nominates Robert Califf as FDA commissioner
President Barack Obama has nominated Dr.
Victoza tops Sanofi's Lyxumia in trial, adding to Novo's GLP-1 arsenal
Competition is heating up in the GLP-1 diabetes market, and Novo Nordisk ($NVO) is doing what it can to line up data behind its long-dominant drug, Victoza.
Takeda joins WIPO Re:Search to accelerate R&D of new drugs for neglected tropical diseases, malaria, TB
Takeda Pharmaceutical Company Limited, a research-based global company, announced its participation in WIPO Re.
Mylan Opens $27.14 Billion Hostile Bid for Perrigo
Shares of Mylan are edging up before the opening bell after the pharmaceutical company went ahead with its hostile, $27.
Glenmark Pharmaceuticals's Bi-Specific Antibody - GBR 1302 To Enter Phase I Trials
- GBR 1302, a HER2xCD3 bi-specific antibody has successfully completed the preclinical evaluation phase- Preclinically, GBR 1302 has demonstrated superiority over current antibody therapies against mo...
Raptor stops developing RP103 drug after it fails to treat nonalcoholic steatohepatitis in children
Raptor Pharmaceutical said that its RP103 (cysteamine bitartrate) drug failed to meet the main goal in a second mid-stage study.
Roche ‘Very Unlikely’ to Pursue a Midsize Acquisition Soon
LONDON— Roche Holding AG is unlikely to pursue midsize acquisitions soon because companies with drugs in late-stage development are too expensive, Chief Executive Severin Schwan said in an interview...
FDA grants Fast Track status for MediciNova's MN-001 to treat idiopathic pulmonary fibrosis
MediciNova, Inc.
La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401
La Jolla Pharmaceutical Company (Nasdaq.
652
653
654
655
656
657
658
